HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDER Asked To Shed More Light On Potential Monograph User Fees

This article was originally published in The Tan Sheet & The Rose Sheet

Executive Summary

While Director Janet Woodcock and other CDER officials explain the center's reasons for proposing a monograph program user fee, some stakeholders suggest the agency explain more about how the program would work.

You may also be interested in...



PCPC: Cosmetic Legislation A Long Shot In 2016, But Objectives Are Clear

The Personal Care Products Council isn't counting on the Personal Care Products Safety Act to pass in 2016, but compromise efforts to reconcile that bill and the Cosmetic Modernization Amendments supported by small business could be the ticket to reform in the 115th Congress, the trade group suggests. PCPC execs discussed the current legislative landscape at the group's annual meeting in Palm Beach, Florida.

Another Advertising Review For Goli Nutrition: Church & Dwight Challenges Ashwagandha Claims

NAD review of Goli claims, looking at weight loss, physical performance, sexual function and sales claims, recommended it modify advertising to avoid conveying implied product efficacy claims for Ashwagandha Gummies and modify or discontinue qualified physical performance claim about ingredient KSM-66.

Perrigo Has First US Approval For OTC Omeprazole Mini-Capsule

Capsule is 70% smaller than tablets of omeprazole currently available in Prilosec OTC and generic equivalents, including formulations Perrigo provides for its private label and store brand customers.

Topics

Related Companies

UsernamePublicRestriction

Register

RS122976

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel